- AU$11.95m
- AU$2.93m
- AU$7.71m
Australia's Immuron gains after completion of stake acquisition in Ateria Health
Brief: Immuron Completes Strategic Investment In Ateria Health Limited
Brief: Immuron Strategic Investment In Leading Gut Health Biotech Ateria Health
Australia's Immuron falls after stake acquisition in UK-based biotech firm
Brief: Immuron Says Signed Subscription And Option Agreement With Gut Health Biotech Ateria Health
Brief: Immuron Says Executed A Master Service Agreement With CPC, Inc
Brief: Immuron Says It Deprioritized SARS-COV-2 Research
Brief: Immuron US DoD Naval Medical Research Center Receives Feedback On on IND Application For New Campylobacter ETEC Therapeutic
Australia's Immuron up on receiving European patent notification
Brief: Immuron Receives European Patent Notification On Drug Composition To Treat Clostridioides Difficile Associated Disease
Brief: Immuron Says Steven Lydeamore Appointed As Chief Executive Office
Australia's Immuron hits over 2-month high on robust global sales
Brief: Immuron Ltd Says Global Sales Up 216% YoY In Q3 FY22
Brief: Immuron Says Request For Au$5.4M Additional Funding From U.S. Department Of Defense For Travelan Considered To Be 'Eligible For Award'
Australia Stock Exchange release from IMMURON : Initial Director's Interest Notice
Australia Stock Exchange release from IMMURON : Appointment of Paul Brennan as Non-Executive Director
Brief: Immuron Ltd Says HY Loss After Tax Attributable A$1.8 Million
Australia Stock Exchange release from IMMURON : PRE_NR Ends: 17:01:03
Australia Stock Exchange release from IMMURON : Half Yearly Report and Accounts